Opinion|Videos|November 1, 2024
Healthcare Resource Utilization Impact of GPRC5D-Targeted Therapies
Panelists discuss how the use of GPRC5D-targeted therapies impacts healthcare resource utilization in the community setting, including potential changes in hospitalizations, outpatient visits, and supportive care needs.
Advertisement
Episodes in this series
- How does the use of GPRC5D-targeted therapies affect healthcare resource utilization, such as hospitalizations, outpatient visits, and supportive care requirements in the community setting?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
SubscribeAdvertisement
Related to this article
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Ralph V. Boccia, MD, FACP, discusses payer models, prior authorization, cost recovery, and patient assistance for bispecifics like teclistamab/daratumumab.
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
Ralph V. Boccia, MD, FACP, details remote monitoring, ICE scoring, CRS prophylaxis, and IVIG strategies for patients receiving bispecifics.
Ralph V. Boccia, MD, FACP, discusses step-up dosing workflows, REMS, staff training, caregivers, and hospital partnerships for bispecifics.
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Advertisement
Advertisement